Apr 6, 2020
CRB’s Dave DiProspero and Noel Maestre were interviewed for Pharmaceutical Technology’s article, “Building Better Manufacturing Facilities.”
Excerpt from PharmTech:
In adding manufacturing capacity—whether through new, greenfield sites or by refitting existing spaces—biopharma and pharma companies seek flexible and efficient production. Getting a facility up and running quickly with a tight budget is increasingly important.
Flexibility is crucial in biopharmaceutical manufacturing, because companies increasingly have multiple modalities (e.g., monoclonal antibodies, cell therapies, and gene therapies) in their pipelines. New biopharma facilities often use single-use technology, and modular buildings and systems are becoming more popular.
The ATMP industry needs to be ready to go big with production—speed is crucial in biologics manufacturing. The rapidly growing market gives hope to people suffering from previously untreatable and rare diseases. But, to make that hope a reality, manufacturers must find a way to produce ATMPs quickly, efficiently and at scale.
And it’s best to start during the preclinical testing phase when you’re still flexible.
In OSD manufacturing, facility layout is becoming more important as equipment and processes are moving toward greater integration.
OSD products may find themselves thrust into the spotlight as their effectiveness against the symptoms of COVID-19 becomes known.
Read MoreListen to Noel Maestre and Emily Thompson's webinar via Cell and Gene Therapy Insights on how to deliver multi-product Advanced Therapy Medicinal Product (ATMP) facilities to adapt to an evolving product pipeline.
Read More
